Shichun Tu

Dr. Shichun Tu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
STShichun Tu
Shichun Tu
MAMohd Waseem Akhtar
Mohd Waseem Akhtar
RERosa Maria Escorihuela
Rosa Maria Escorihuela
AAAlejandro Amador-Arjona
Alejandro Amador-Arjona
VSVivek Swarup
Vivek Swarup
NNNobuki Nakanishi
Nobuki Nakanishi
Transcription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy. However, molecular mechanisms underlyingMEF2Chaploinsufficiency syndrome remain poorly understood. Here we report thatMef2c+/−(Mef2c-het) mice exhibit behavioral deficits resembling those of human patients. Gene expression analyses on brains from these mice show changes in genes associated with neurogenesis, synapse formation, and neuronal cell death. Accordingly,Mef2c-het mice exhibit decreased neurogenesis, enhanced neuronal apoptosis, and an increased ratio of excitatory to inhibitory (E/I) neurotransmission. Importantly, neurobehavioral deficits, E/I imbalance, and histological damage are all ameliorated by treatment with NitroSynapsin, a new dual-action compound related to the FDA-approved drug memantine, representing an uncompetitive/fast off-rate antagonist of NMDA-type glutamate receptors. These results suggest thatMEF2Chaploinsufficiency leads to abnormal brain development, E/I imbalance, and neurobehavioral dysfunction, which may be mitigated by pharmacological intervention.

1 April 2018 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
LGLingchuan Guo
Lingchuan Guo
PLPei NA Lin
Pei NA Lin
HXHui Xiong
Hui Xiong
STShichun Tu
Shichun Tu
GCGang Chen
Gang Chen

21 November 2019 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
ZZZunmin Zhu
Zunmin Zhu
TLTao Li
Tao Li
XZXuran Zhang
Xuran Zhang
ZZZhengqiang Zhang
Zhengqiang Zhang
DZDandan Zhu
Dandan Zhu
HRHongwei Ren
Hongwei Ren
Although the majority of patients with follicular lymphoma (FL) harbor the t(14;18)(q32;q21) IGH/BCL2 gene rearrangement that leads to the overexpression of BCL2 protein, approximately 20% of FL cases lack t(14;18) (q32;q21). It is considered that BCL2 overexpression underscores the development of the majority of cases of FL and their transformation to more aggressive lymphoma [known as transformed FL (tFL)]. However, FL cases lacking the t(14;18) (q32;q21) translocation exhibit symptoms analogous to their t(14;18)-positive counterparts. An important goal of recent research on FL has been to clarify the distinctions between the two different forms of FL. Numerous studies have shed light onto the genetic and molecular features of t(14;18)-negative FL and the related clinical manifestations. In this review, we summarize the current knowledge of t(14;18)-negative FL occurring in the lymph nodes with an emphasis on the underlying molecular and clinical features. In addition, novel treatment directions are discussed.

11 March 2024 in Oncology Letters
Verified
Journal Article
Open access
PDF file
YXYasi Xing
Yasi Xing
FQFangyuan Qin
Fangyuan Qin
LHLei Han
Lei Han
JYJingwen Yang
Jingwen Yang
HZHongrui Zhang
Hongrui Zhang
YZYaping Zhai
Yaping Zhai
The 5‑year survival rate of patients with advanced non‑small cell lung cancer (NSCLC) remains low, despite recent advances in targeted therapy and immunotherapy. Therefore, there is a need to identify alternative strategies to improve treatment outcomes. Modern diagnostics can significantly facilitate the selection of treatment plans to improve patient outcomes. In the present study, multi‑form diagnostic methodologies were adopted, including next‑generation sequencing‑based actionable gene sequencing, programmed death ligand 1 (PD‑L1) immunohistochemistry, a circulating tumor cell (CTC) assay, flow cytometric analysis of lymphocyte subsets and computed tomography, to improve disease management in an 86‑year‑old female patient with relapsed metastatic NSCLC. High expression of PD‑L1, elevated CTC tmutations, were observed. Based on these results, the patient was initially treated with the programmed death protein 1 blocking antibody sintilimab for two cycles, resulting in the stabilization of their condition, although the patient still exhibited severe pain and other symptoms, including fatigue, malaise, a loss of appetite and poor mental state. Informed by dynamic monitoring of the patient's response to treatment, the treatment plan was subsequently adjusted to a combination therapy with sintilimab and autologous cytokine‑induced killer cell infusion, which eventually led to improved outcomes in both the management of the cancer and quality of life. In conclusion, multi‑omics analysis may be used to establish patient‑tailored therapies to improve clinical outcomes in hard‑to‑treat elderly patients with metastatic NSCLC.